Kurt

 


Home
CV
Research
Publications & Presentations
scrap
blog
Contact Me

     Related Pages

  • Imagenetics METRICS: Implementation of Genetic Testing at Sanford Health. CHeRP/PROMoTeR Seminar, Maine Medical Center; Harvard Pilgrim Health Care Institute; Jul 2020, Boston, MA.

  • Impact of Integrating Genetic Testing into General Medicine. Department of Population Medicine "Brown Bag" Presentation, Harvard Pilgrim Health Care Institute; Jul 2020, Boston, MA.

  • Precision Medicine Policy and Treatment (PreEMPT) Model. Department of Population Medicine "Brown Bag" Presentation, Harvard Pilgrim Health Care Institute; Dec 2019, Boston, MA.

  • Will polygenic risk scores and preventive genomics deliver in precision medicine? Maine Medical Center Research Institute. University of Florida Precision Medicine Conference, Maine Medical Center; Feb 2020, Orlando, FL.

  • Genomic Screening: What's the Value? Maine Medical Center Research Institute. Center for Outcomes Research and Evaluation, Maine Medical Center; Nov 2019, Portland, ME.

  • Econogenomics: is genomic testing worth the cost? Stanford Center for Biomedical Ethics; Nov 2019, Teleconference.

  • Evaluating the Economic Impact of Genomic Testing During Clinical Trials. American Society for Human Genetics Annual Meeting; Oct 2019, Houston, TX.

  • Global Developments in Artificial Intelligence and Machine Learning in Healthcare. International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; May 2019; New Orleans, LA.

  • Screening newborns with genomic sequencing increases short-term downstream health care costs: preliminary findings from the BabySeq Project. Pediatric Acadamic Societies Meeting; Apr 2019; Baltimore, MD.

  • Screening newborns with genomic sequencing increases short-term downstream health care costs: preliminary findings from the BabySeq Project. American College of Medical Genetics Annual Meeting; Apr 2019; Seattle, WA.

  • Patient-reported outcomes in a pilot randomized trial of genome sequencing. Selected for poster presentation at the 2018 International Society for Pharmacoeconomics and Outcomes Research Europe Meeting; Nov 2018; Barcelona, Spain.

  • Impact of disclosing genetic risk for Alzheimer’s disease to patients with mild memory problems. Selected for oral presentation at the Gerontological Society of America's 2018 Annual Scientific Meeting. Nov 2018; Boston, MA

  • The science of surveys: interactive session on the foundations of survey design and implementation to improve genetic counselor research and clinical practice. National Society of Genetic Counselors Annual Meeting; Nov 2018; Atlanta, GA

  • Empirical approaches to medical and economic outcomes in genomic medicine. Keynote address at the 7th Annual Sanford Imagenetics Genomic Medicine Symposium; Sep, 2018; Sioux Falls, SD

  • Changes to willingness to pay for whole genome sequencing after experience. Selected for poster presentation at the American College of Medical Genetics Annual Meeting; Apr 2018; Charlotte, NC.

  • Medically reportable outcomes and cost implications of newborn sequencing in the BabySeq project. Oral presentation at the Frontiers in Pediatric Genomic Medicine Conference; Apr 2018; La Jolla, CA

  • Short-term costs of integrating whole genome sequencing into cardiology and primary care. Oral presentation at the World Precision Medicine Congress; Nov 2018; Washington, DC

  • Behavioral and psychological responses to whole genome sequencing: Findings from the MedSeq Project. Poster presentation at the Broad Institute Annual Retreat; Dec 2017; Boston, MA.

  • What REVEAL and MedSeq tell us about the future of precision medicine American Academy of Neurology Annual Meeting Boston, MA

  • The impact of integrating genome sequencing into the care of healthy patients. Oral presentation at the Cornell Center for Comparative and Population Genomics seminar; Mar 2017; Ithaca, NY

  • Clinician Bake Off update. Oral presentation at the Clinical Sequencing Exploratory Research Consortium meeting; Feb 2017; Bethesda, MD

  • Is genomic sequencing worth the costs? Learning Lounge presentation at the American College of Medical Genetics Annual Meeting; Apr 2017; Phoenix, AZ

  • Cardiologists' responses to whole genome sequencing: preliminary findings from the MedSeq Project. Poster presentation at the American Society of Human Genetics Annual Meeting; Oct 2016; Vancouver, BC.

  • Using whole genome sequencing to motivate lifestyle changes: preliminary findings from the MedSeq Project. Poster presentation at the American College of Medical Genetics Annual Meeting; Mar 2016; Tampa, FL.

  • Responses of primary care physicians to unsolicited secondary findings about Lynch syndrome. Oral presentation at the American Society of Human Genetics Annual Meeting; Oct 2015; Baltimore, MD.

  • Patient perceptions about the utility of family history review during whole genome sequencing: initial findings from the MedSeq Study. Selected for oral presentation at the American Society of Human Genetics Annual Meeting; Oct 2014; San Diego, CA.

  • “Somebody translate this information for me:” Physician perceptions of their preparedness to disclose full genome sequencing results. Poster presentation at the American College of Medical Genetics Annual Meeting; Mar 2014; Nashville, TN.

  • What is the long-term emotional and behavioral impact of genetic risk assessment for Alzheimer's disease? Findings from the REVEAL Study. Selected for oral presentation at the Alzheimer's Association International Conference; Jul 2014; Copenhagen.

  • Short-term psychological benefits to consumer genetic testing: findings from the PGen Study. Selected for oral presentation at the American Public Health Association Annual Meeting; Nov 2013; Boston, MA.

  • Psychological responses to genetic risk disclosure among individuals at imminent risk for Alzheimer’s disease and their study partners: findings from the REVEAL Study. Selected for poster presentation at the annual meeting of the American Society of Human Genetics; Nov 2013; Boston, MA.

  • Emotional responses to personal genomic testing. Poster presentation at the 2013 Consumer Genetics Conference.

  • The psychological impact of genetic risk information on individuals with mild cognitive impairment at imminent risk for conversion to Alzheimer’s disease dementia: findings from the REVEAL Study. Oral presentation at the 2013 Alzheimer’s Association International Conference.

  • Self-referral to genetic susceptibility testing for Alzheimer’s disease: implications for uptake and responses to results. Poster presentation at the 2013 annual meeting of the American College of Medical Genetics.

  • Changes to control perceptions following disclosure of APOE-coronary artery disease associations during genetic susceptibility testing for Alzheimer’s disease: Findings from the REVEAL Study. Oral presentation at the American Society of Human Genetics 62nd Annual Meeting.

  • Disclosing individual CDKN2A research results to melanoma survivors: Interest, impact, and demands on researchers. Platform presentation at the 2011 annual meeting of the American College of Medical Genetics.

  • Telephone and in-person disclosure of genetic test results: 6-week recall, comprehension, and distress among participants in the REVEAL Study. Poster presentation at the 2010 Annual Meeting of the American Public Health Association.

  • Changes in physical activity but not diet following disclosure of pleiotropic information during genetic risk assessment for Alzheimer’s disease: Findings from the REVEAL Study. Poster presentation at the 2010 Annual Meeting of the American Society of Human Genetics.

  • Telephone and in-person disclosure of genetic test results: 6-week recall, comprehension, and distress among participants in the REVEAL Study. Poster presentation at the 2010 Genome Science Institute Research Symposium.

  • The psychological impact of learning APOE ε4 increases the risk for cardiovascular disease during genetic risk assessment for Alzheimer’s disease: Findings from the REVEAL Study. Oral presentation at the 2010 International Conference on Alzheimer’s Disease.

  • Perceived personal utility of Alzheimer’s disease genetic susceptibility testing and its influence on post-test responses: Findings from the REVEAL Study. Oral presentation at the 2010 Communications, Medicine and Ethics conference.

  • Implementation and impact of a protocol to disclose individual genetic information to research participants. Oral presentation at the first annual Bioethics Research Colloquium at the University of Michigan.

  • How does pleiotropic information affect health behavior changes? Initial results from the REVEAL Study, a randomized trial of genetic testing for Alzheimer’s disease. Oral presentation at the 2010 annual meeting of the American College of Medical Genetics.

  • Black and white Americans’ understandings of genetics. Oral presentation at the 2009 annual meeting of the American Public Health Association.

  • The Impact of Pleiotropic Information about Cardiovascular Disease Risk on Health Behavior Changes among People Seeking Genetic Susceptibility Testing for Alzheimer’s Disease: Initial Results from a Randomized Trial. Poster presentation at the inaugural GAPPNet meeting.

  • The Impact of an Education and Risk Evaluation Protocol on Perceived Benefits, Risks and Limitations of Genetic Susceptibility Testing for Alzheimer’s Disease. Poster presented at the Alzheimer's Association International Conference on Alzheimer’s Disease.

  • Incorporating Ethnicity into Genetic Risk Assessment for Alzheimer’s Disease: The REVEAL Study Experience. Poster presented at the Alzheimer's Association International Conference on Prevention of Dementia.

  • Information Needs of Traditionally Underserved Clients and Care Providers in Washington, DC. Poster presented at the American Society for Human Genetics Annual Meeting.